POLYMORPHISMS IN THE ACE2 AND IL-6 GENES AND THEIR POTENTIAL IMPACT ON THE SUSCEPTIBILITY OF SEVERE COVID-19 AMONG ERBIL HOSPITALIZED PATIENTS
Polymorphisms in the ACE2 and IL-6 genes and COVID-19
DOI:
https://doi.org/10.25271/sjuoz.2024.12.2.1282Keywords:
COVID-19 , ACE2, Angiotensin, converting enzyme 2, IL-6; Interleukin -6, PolymorphismsAbstract
Severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) is a transmissible illness caused worldwide pandemic. This virus invades host cells via receptors of angiotensin-converting enzyme 2 (ACE2). Moreover, the viral infection stimulates the production of a variety of cytokines like interleukin-6 (IL-6). The main aim of this work is to investigate the connection between COVID-19 and polymorphism of ACE2 (rs2106809 and rs2285666) and IL-6 (-174 G/C) (rs1800795) genes in a group of patients. Genomic DNA was prepared from the peripheral blood of 60 hospitalized patients and 22 controls, the ACE2 and IL-6 genes were amplified by PCR, and the products were sequenced. The data demonstrated a significant variation in the genotype frequency of ACE2 between COVID-19 patients and healthy subjects.The ACE2 (rs2106809) polymorphism outcomes expressed the frequency of three genotypes (TT, TC, and CC), the patients with the TC allele are at risk of developing the disease by approximately 8-folds (OR= 7.5) compared to those with TT and CC alleles. Furthermore, no significant association was found between ACE2 (rs2285666) polymorphism and the risk of developing SARS-CoV-2 which showed a frequency of (AA, AG, and GG) alleles. Additionally, there was no noticeable linkage between the (GG, CC, and CG) genotypes of IL-6 (−174 G/C) (rs1800795) and the hazard of contracting COVID-19. In conclusion, this investigation confirmed that the TC genotype of ACE2 (rs2106809) polymorphism represents a risk factor for acquiring COVID-19 and proposed to perform a critical action in the severity of pathogenicity in Iraqi Kurdish people.
References
Abed, T. A., Utba, N. M., & Abdulkarem, A. H. (2023). Assessing the correlation between SNP rs1800795 genotypes to serum Interleukin- 6 levels among COVID-19 patients in Iraq. Biomedicine, 43(5), 1490–1495.
Allami, R. H., Hassoon, A. H., Abdulateef, Y. M., Ghani, A. A., & Al-Falahi, S. J. (2023). Genetic Association of Angiotensin-converting enzyme 2 ACE-2 (rs2285666) Polymorphism with the Susceptibility of COVID-19 Disease in Iraqi Patients: Tropical Journal of Natural Product Research, 7(2): 2346–2351.
Chaudhary, M. (2020). COVID-19 susceptibility: potential of ACE2 polymorphisms. Egyptian Journal of Medical Human Genetics, 21(1): 1-8.
Chen, Y., Liu, Q., & Guo, D. (2020). Emerging coronaviruses: Genome structure, replication, and pathogenesis. Journal Medical Virology, 92(4): 418–423.
Ciaglia, E., Vecchione, C., & Puca, A. A. (2020). COVID-19 Infection and Circulating ACE2 Levels: Protective Role in Women and Children. Frontiers in Pediatrics, 8(2020): 545005.
Devaux, C. A., Rolain, J. M., & Raoult, D. (2020). ACE2 receptor polymorphism: Susceptibility to SARS-CoV-2, hypertension, multi-organ failure, and COVID-19 disease outcome. Journal of Microbiology, Immunology, and Infection, 53 (3): 425–435.
Dhabaan, A. A. N., Hamad, A. K., & Hassoon, A. H. (2022). Association Between COVID-19 Risk and the Genotypes (GG, GC, and CC)and its G and C Alleles for Interlukin-6 (IL-6) gene Polymorphisms. HIV Nursing, 22(2): 567–570.
Falahi, S., Zamanian, M. H., Feizollahi, P., Rezaiemanesh, A., Salari, F., Mahmoudi, Z., & Gorgin Karaji, A. (2022). Evaluation of the relationship between IL-6 gene single nucleotide polymorphisms and the severity of COVID-19 in an Iranian population. Cytokine, 154:155889.
Fishchuk, L., Rossokha, Z., Pokhylko, V., Cherniavska, Y., Tsvirenko, S., Kovtun, S., Medvedieva, N., Vershyhora, V. and Gorovenko, N. (2022) Modifying effects of TNF-α, IL-6 and VDR genes on the development risk and the course of COVID-19. Pilot study. Drug Metabolism and Personalized Therapy, 37(2):133-139.
Ghazy, A,A. (2023). Influence of IL-6 rs1800795 and IL-8 rs2227306 polymorphisms on COVID-19 outcome. Journal of Infection in Developing Countries, 2023 Mar 31;17(3):327-334.
Jevnikar, K., Lapajne, L., Petrovič, D., Meglič, A., Logar, M., Valentinčič, N. V., Petrovič, M. G., Cilenšek, I., & Mekjavić, P. J. (2022). The Role of ACE, ACE2, and AGTR2 Polymorphisms in COVID-19 Severity and the Presence of COVID-19-Related Retinopathy. Genes, 13(7).
Karakaş Çelik, S., Çakmak Genç, G., Pişkin, N., Açikgöz, B., Altinsoy, B., Kurucu İşsiz, B., & Dursun, A. (2021). Polymorphisms of ACE (I/D) and ACE2 receptor gene (Rs2106809, Rs2285666) are not related to the clinical course of COVID-19: A case study. Journal of Medical Virology, 93(10): 5947–5952.
Keikha, M., & Karbalaei, M. (2022). Global distribution of ACE1 (rs4646994) and ACE2 (rs2285666) polymorphisms associated with COVID-19: A systematic review and meta-analysis. Microbial Pathogenesis, 172: 105781
Kerget, F., & Kerget, B. (2021). Frequency of interleukin-6 rs1800795 (-174G/C) and rs1800797 (-597G/A) polymorphisms in COVID-19 patients in Turkey who develop macrophage activation syndrome. Japanese Journal of Infectious Diseases, 2021 Nov 22;74(6):543-548.
Kirtipal, N., & Bharadwaj, S. (2021). Interleukin 6 polymorphisms as an indicator of COVID-19 severity in humans. Journal of Biomolecular Structure and Dynamics, 39(12): 4563–4565.
Lippi, G., Lavie, C. J., Henry, B. M., & Sanchis-Gomar, F. (2020). Do genetic polymorphisms in angiotensin-converting enzyme 2 (ACE2) gene play a role in coronavirus disease 2019 (COVID-19)? Clinical Chemistry and Laboratory Medicine, 29;58(9):1415-1422.
Liu, M. Y., Zheng, B., Zhang, Y., & Li, J. P. (2020). Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019. Chronic Diseases and Translational Medicine, 6(2):98-105.
Najafi, M., & Mahdavi, M. R. (2023). Association investigations between ACE1 and ACE2 polymorphisms and severity of COVID-19 disease. Molecular Genetics and Genomics, 298(1):27-36.
Öztürk, R., Taşova, Y., & Ayaz, A. (2020). Covid-19: Pathogenesis, genetic polymorphism, clinical features and laboratory findings.Turkish Journal of Medical Sciences,50 (SI-1):638-657.
Parsons, P. E., Eisner, M. D., Thompson, B. T., Matthay, M. A., Ancukiewicz, M., Bernard, G. R., & Wheeler, A. P. (2005). Lower tidal volume ventilation and plasma cytokine markers of inflammation in patients with acute lung injury. Critical Care Medicine, 33(1):1-6.
Pouladi, N., & Abdolahi, S. (2021). Investigating the ACE2 polymorphisms in COVID-19 susceptibility: An in silico analysis. Molecular Genetics & Genomic Medicine, 9(6):e1672.
Rokni, M., Sarhadi, M., Heidari Nia, M., Mohamed Khosroshahi, L., Asghari, S., Sargazi, S., Mirinejad, S., & Saravani, R. (2022). Single nucleotide polymorphisms located in TNFA, IL1RN, IL6R, and IL6 genes are associated with COVID-19 risk and severity in an Iranian population. Cell Biology International,46(7):1109-1127.
Sambrook, j., & Russell, D. W. (2001). Molecular cloning : A laboratory manual (Vol. 1). Cold Spring Harbor Laboratory Press.
Sidhwani, S. K., Mirza, T., Khatoon, A., Shaikh, F., Khan, R., Shaikh, O. A., & Nashwan, A. J. (2023). Angiotensin-converting enzyme 2 (ACE2) polymorphisms and susceptibility of severe SARS-CoV-2 in a subset of Pakistani population. Virology Journal, 20(1): 120.
Srivastava, A., Bandopadhyay, A., Das, D., Pandey, R. K., Singh, V., Khanam, N., Srivastava, N., Singh, P. P., Dubey, P. K., …..(2020). Genetic Association of ACE2 rs2285666 Polymorphism With COVID-19 Spatial Distribution in India. Frontiers in Genetics, 11:564741.
Sun, P., Lu, X., Xu, C., Sun, W., & Pan, B. (2020). Understanding of COVID-19 based on current evidence. Journal of Medical Virology, 92(6): 548-551.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation, immunity, and disease. Cold Spring Harbor Perspectives in Biology, 6(10):a016295.
Technologies Corporation, L. (2014). TaqMan® Universal PCR Master Mix User Guide (Pub. no. 4304449 Rev. E). Manual, 4304449.
Turner, AJ, Hooper, NM.( 2002). The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacology Sciences, 23:177–83.
Ulhaq, Z. S., & Soraya, G. V. (2020). Anti-IL-6 receptor antibody treatment for severe COVID-19 and the potential implication of IL-6 gene polymorphisms in novel coronavirus pneumonia. Medicina Clinica, 155(12): 548–556.
Vitkauskaite, A., Celiesiute, J., Juseviciute, V., Jariene, K., Skrodeniene, E., Samuolyte, G., Nadisauskiene, R. J., & Vaitkiene, D. (2021). Il-6 597a/g (Rs1800797) and 174g/c (rs1800795) gene polymorphisms in the development of cervical cancer in Lithuanian women. Medicina (Kaunas), 57(10):1025
Wang, X., Guo, X., Prof, A., Xin, Q., & Pan, Y. (2020). Neutralizing Antibodies Responses to SARS-CoV-2 in COVID-19 Inpatients and Convalescent Patients. Clinical Infectious Diseases, 71(10):2688-2694.
Zhang, X., Li, S., & Niu, S. (2020). ACE2 and COVID-19 and the resulting ARDS. Postgraduate Medical Journal, 96(1137):403-407.
Zhou, P., Yang, X. Lou, Wang, X. G., Hu, B., Zhang, L., Zhang, W., Si, H. R., Zhu, Y., Li, B., Huang, C. L., Chen, H. D.,., … Shi, Z. L. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579(7798): 270–273.
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Khlood N. Saeed, Bushra H. Shnawa, Adnan I. Al-Badran
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License [CC BY-NC-SA 4.0] that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work, with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online.
